Kazia Therapeutics Files 6-K Report
Ticker: KZIA · Form: 6-K · Filed: Oct 2, 2025 · CIK: 1075880
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer
Related Tickers: KZA
TL;DR
Kazia Therapeutics (KZA) filed a 6-K, standard foreign issuer report.
AI Summary
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on October 2, 2025. The company, based in Sydney, NSW, Australia, is a foreign private issuer and is submitting its report under the Securities Exchange Act of 1934. Kazia Therapeutics is involved in the pharmaceutical preparations industry.
Why It Matters
This filing indicates ongoing reporting requirements for Kazia Therapeutics as a foreign private issuer, providing transparency to investors about its regulatory status.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain new financial or operational information.
Key Players & Entities
- Kazia Therapeutics Limited (company) — Registrant
- Novogen Ltd (company) — Former company name
- October 2, 2025 (date) — Filing date
- Sydney NSW (location) — Company address
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934. It is used to furnish information which the issuer makes or is required to make public pursuant to the laws of its home country, or which it furnishes or makes public to its security holders.
When was this Form 6-K filed?
This Form 6-K was filed on October 2, 2025.
What is Kazia Therapeutics Limited's principal executive office address?
Kazia Therapeutics Limited's principal executive office is located at Three International Towers Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
Is Kazia Therapeutics Limited a foreign private issuer?
Yes, the filing explicitly states that Kazia Therapeutics Limited is a foreign private issuer.
What was Kazia Therapeutics Limited's former company name?
Kazia Therapeutics Limited's former company name was Novogen Ltd, with a date of name change on December 28, 1998.
Filing Stats: 293 words · 1 min read · ~1 pages · Grade level 13.9 · Accepted 2025-10-02 08:55:51
Filing Documents
- d68992d6k.htm (6-K) — 9KB
- d68992dex991.htm (EX-99.1) — 9KB
- 0001193125-25-227551.txt ( ) — 19KB
From the Filing
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant's name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-FForm 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): INFORMATION CONTAINED IN THIS FORM 6-K REPORT On October 2, 2025, Kazia Therapeutics Limited (the "Company") issued a press release titled "Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen." A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quote of Dr. John Friend, Chief Executive Officer of the Company, contained in Exhibit 99.1, into the Company's registration statement on Form F-3 (File No. 333-281937). EXHIBIT LIST Exhibit Description 99.1 Press Release of Kazia Therapeutics Limited dated October 2, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Kazia Therapeutics Limited (Registrant) /s/ John Friend John Friend Chief Executive Officer Date: October 2, 2025